Novavax (XSWX:NVAX) Total Equity: CHF-114.0 Mil (As of Mar. 2026)


XSWX:NVAX Novavax Inc XSWX:NVAX
50 GF Score
Price CHF7.61
GF Value CHF3.14
! 7 Warning Signs
View Full Analysis

What is Novavax Total Equity?

Novavax XSWX:NVAX -1.78% 50 Total Equity is CHF-114.0 Mil as of Mar. 2026. GuruFocus rates XSWX:NVAX with a GF Score™ of 50/100 and a GF Value™ of CHF3.14. The stock has 7 warning signs investors should review.

Novavax's total equity for the quarter that ended in Mar. 2026 was CHF-114.0 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Novavax Total Equity Historical Data

* Premium members only.

The historical data trend for Novavax's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax Total Equity Chart

Novavax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -323.89 -590.71 -620.00 -556.22 -101.81

Novavax Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -66.84 30.60 -124.73 -101.81 -113.97
XSWX:NVAX
50GF Score
Novavax Inc XSWX:NVAX
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Novavax's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=937.562-1039.369
=-101.8

Novavax's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=821.281-935.253
=-114.0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of CHF-114.0 Mil mean?
Novavax (XSWX:NVAX) has a Total Equity of CHF-114.0 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Novavax and its competitors.
Is Novavax's Total Equity too high?
Novavax's current Total Equity is CHF-114.0 Mil. Overall, Novavax has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Novavax's Total Equity compare to MPLT and COAG?
Novavax's Total Equity of CHF-114.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Novavax and its competitors. Novavax's current Total Equity is CHF-114.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Novavax (XSWX:NVAX) has a current Total Equity of CHF-114.0 Mil. The stock's GF Value™ is CHF3.14, compared to a current price of CHF7.61 — trading 142.4% above its estimated fair value. The current Total Equity is CHF-114.0 Mil. Novavax's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Novavax (XSWX:NVAX), the current Total Equity is CHF-114.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novavax (XSWX:NVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of CHF7.61 is trading 142.4% above its estimated GF Value™ of CHF3.14.

Key valuation signals for XSWX:NVAX:

  • Total Equity: CHF-114.0 Mil
  • GF Value™: CHF3.14 vs. price of CHF7.61 (142.4% above fair value)
  • GF Score™: 50/100 with 7 warning signs

No single metric tells the full story. See the XSWX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
50GF Score

Get the complete analysis for XSWX:NVAX

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF7.61
Price
CHF3.14
GF Value